Quality Control/Quality Assurance Reviews for CTSA Submissions

总体UL1：摘要前沿：堪萨斯大学临床与翻译科学研究所 是将翻译科学研究人员和KC地区的利益相关者聚集在一起的催化剂， 以及更远的地方。位于KUMC，在Mario Castro医学博士，公共卫生硕士的领导下，我们致力于团队 科学和多学科合作超越了我们学术健康科学中心的界限 并促进来自不同学科的研究人员在当地合作伙伴学术机构之间的合作 医疗机构及附属医疗机构(堪萨斯城儿童慈善会、密苏里大学-堪萨斯分校 城市，圣卢克医疗系统，堪萨斯大学医疗系统，堪萨斯城市医科大学 和生物科学，以及堪萨斯州立大学)。前沿的愿景是为国家做出贡献并领导国家 努力改变我们进行临床和转化性研究(CTR)的方式，并确保研究更多 迅速和更有效地将其转化为护理点，从而可能有助于改善健康。 具体而言，Frontiers的目标是：1)与所有利益攸关方进行双向合作，以开发、 展示并传播跨翻译科学领域的进展，以确保纳入和 在从出生到生命终结的整个生命过程中，融合复杂多样的人口和个人；2) 打造一支由多学科调查人员、研究人员和 社区和患者利益相关者通过创新和创造性使用翻译科学工具 计划；以及3)加强机构和地区基础设施，以加快翻译研究。我们 将通过利用我们的相当大的优势来实现这些目标：a)开发信息学工具 使EHR数据做好研究准备，并实施基于诊所和社区的研究登记 招聘和其他翻译研究应用；b)培养和维持强大的耐心和 社区参与关系将支持与非洲裔美国人、拉美裔美国人和美国人的研究 印度、LGBTQ、儿科、老年病、罕见病、监狱和农村人口；c)提供创新培训 面向整个CTR工作人员(不仅仅是调查人员)的计划，包括全面的 创业和实施研究培训和创建新团队科学集思广益 将导致多学科发现项目的机制以及d)先进的医疗设备和重新 通过前沿先进医学研究所开发的新策略为患者提供有针对性的药物 以产品开发、翻译研究和高影响力而闻名全国的创新 与工业界、学术界、政府和疾病慈善合作伙伴的合作。所有边境单位都是 由一组可由Frontiers调查团队和社区访问的导航器链接 合伙人。这些计划使前沿为实现目标作出贡献，并通过以下方式领导CTSA网络的倡议 以技术、计算和健康/疾病知识为基础，推进转化性研究。

OVERALL UL1: ABSTRACT Frontiers: University of Kansas Clinical and Translational Science Institute has been a catalyst for bringing together translational science investigators and stakeholders across the KC region, and beyond. Located at KUMC under the leadership of Mario Castro, MD, MPH, our commitment to team science and multidisciplinary collaboration reaches beyond the walls of our academic health science center and promotes collaboration among investigators from diverse disciplines across local partner academic institutions and affiliated health care institutions (Children’s Mercy Kansas City, University of Missouri-Kansas City, Saint Luke’s Health System, The University of Kansas Health System, Kansas City University of Medicine and Biosciences, and Kansas State University). The vision of Frontiers is to contribute to and lead national efforts to transform the way we do clinical and translational research (CTR), and to ensure research is more rapidly and more efficiently translated to the point of care so that it may contribute to improved health. Specifically, Frontiers aims to: 1) Engage in bi-directional collaboration with all stakeholders to develop, demonstrate, and disseminate advances across the translational science spectrum that insures inclusion and integration of complex and diverse populations and individuals across the lifespan from birth to end of life; 2) Create a sustainable translational workforce of multi-disciplinary investigators, research personnel, and community and patient stakeholders in the use of translational science tools through innovative and creative programs; and 3) Strengthen institutional and regional infrastructure to accelerate translational research. We will accomplish these aims by drawing on our considerable strengths: a) developing informatics tools for making EHR data ‘research ready’ and implementing clinic- and community-based registries for study recruitment and other translational research applications; b) nurturing and sustaining strong patient and community engagement relationships that will support research with African American, Latino, American Indian, LGBTQ, pediatric, geriatric, rare disease, prison, and rural populations; c) offering innovative training programs for the entire CTR workforce (not just investigators), including plans for comprehensive entrepreneurship and implementation research training and creating new team science brainstorming mechanisms that will lead to multidisciplinary discovery projects and d) advancing medical devices and re- purposed drugs to patients through novel strategies developed by Frontiers’ Institute for Advancing Medical Innovations that is nationally known for its product development translational research and high impact collaborations with industry, academia, government, and disease philanthropy partners. All Frontiers units are linked by a group of Navigators that can be accessed by Frontiers investigative teams and community partners. These plans position Frontiers to contribute to goals, and lead initiatives of the CTSA network by building on technological, computational, and health/disease knowledge to advance translational research.